Accelerate your precision
oncology drug development
Incorporate real-world clinical genomic insights to improve your biomarker-driven clinical trial design, with potential impact on inclusion and exclusion criteria, endpoint selection, and stratification of treatment regimen. With data from over 175,000 patients, our GuardantINFORM™ real-world clinical-genomic platform is one of the largest of its kind. This robust dataset offers insights into anti-cancer therapy use in the clinic, tumor evolution, and treatment resistance throughout each patient’s treatment journey.
Utilize GuardantINFORM at all phases of drug development: